Background
Classical immune checkpoints
Novel immune checkpoints
Target | Chromosomal location | Binding partner | Expression |
---|---|---|---|
VISTA | 10q22.1 | VSIG3 | Myeloid cells, T cells |
CD38 | 4p15.32 | CD31 | Non-hematopoietic cells, immune cells |
CD39 | 10q24.1 | Unknown | B cells, NK cells, DCs, monocytes, macrophages, Tregs |
CD73 | 6q14.3 | Unknown | endothelial cells, lymphocytes, tumor cells, stromal cells |
LAG-3 | 12p13.31 | MHC-II, galectin-3, LSECtin, a-synuclein, FGL1 | Activated T cells, B cells, Tregs, NK cells, DCs |
IDO-1 | 8p11.21 | AhR | DCs, eosinophils, tumor cells |
CD27 | 12p13.31 | CD70 | T cells, B cells, plasma cells, NK cells |
TIM-3 | 5q33.2 | Galectin-9, Ceacam-1, HMGB1, PtdSer | Activated T cells, B cells, Tregs, DCs, NK cells, monocytes |
CD47 | 3q13.12 | SIRPA | Human cells, tumor cells |
CD93 | 20p11.21 | IL-17D | Endothelial cells |
CD161 | 12p13.31 | LLT1 | NK cells, T cells |
BTLA | 3q13.2 | HVEM | Mature B cells, T cells, Tregs, macrophages, DCs |
VTCN1 | 1p13.1-p12 | Unknow | Antigen-presenting cells |
B7-H3 | 15q24.1 | Unknow | Activated T cells, NK cells, DCs, monocytes, tumor cells |
TIGIT | 3q13.31 | CD155, CD112, CD113 | NK cells, activated T cells, Tregs, follicular T helper cells |
VISTA
Structure and function
Clinical trials on VISTA (Table 2)
-
CA-170 is one of the first agents for a clinical trial. As PD‐L1, PD‐L2, and VISTA antagonist, CA-170 is uncovered to work with silenced T cells and block cytokine secretion by recognizing the binding sites conserved in VISTA [60, 64]. It is the first oral immune checkpoint inhibitor, and data from the clinical trial (NCT02812875) ensured its pharmacological safety and effectiveness. The completed phase I study was conducted on 71 adult patients suffering from advanced solid tumors or lymphomas who progressed or were non-responsive to available therapies. Participants were given CA-170 orally once or twice daily. The result showed an acceptable safety profile and a relatively shorter pharmacokinetics (PK) exposure with a t1/2 of 3.4 h for CA-170. Evidence of peripheral T cell activation was proved by the increased proportion of circulating CD8+ and CD4+ T cells expressing activation markers, CD69 and Granzyme B and OX-40 (CD134).
-
Another monoclonal antibody that blocks the immune inhibition of VISTA, VSTB112, is also under commercial and therapeutic development [60]. As an anti‐VISTA monoclonal antibody (mAb), VSTB112 links to an epitope consisting of C–C′ loops and adjacent helix, VISTA with VSIG3 and PSGL-1 [63]. The phase I trial on the anti-VISTA antagonist, VSTB112 (JNJ-61610588, NCT02671955), was launched in January 2016 by Janssen Research & Development. In this trial, participants were given intravenous infusions of JNJ-61610588 until disease progression. Unfortunately, the whole research was terminated due to financial concerns.
-
SG7 is a species cross-reactive antibody against murine, cynomolgus monkey, and human VISTA with high affinity [63]; the binding between VISTA and SG7 relies on H122 and E125, located on the histidine-rich tip of VISTA, blocking the bination of VISTA and PSGL-1/VSIG3. In the study, researchers chose splenocytes from C57BL/6 mice that were activated by anti-CD3/anti-CD28 beads and incubated them with mVISTA-Fc in a complex with SG7 concentration gradient at pH 6.0, then found the binding of mVISTA-Fc with mouse T cells was blocked by SG7 in a dose-dependent manner, where SG7 completely stopped the interaction at the dose of > 10 nM. In human T cells, a dose-dependent reaction was observed when activated CD4+/CD8+ cells were incubated to hVISTA-Fc, in which > 50 nM SG7 also suppressed the hVISTA/T cell bination [59]. Till now, at least 24 clinical trials have been registered on ClinicalTrials.gov, though no result has been reported.
CD73, CD39, and CD38
Structure and function
Target | Drug | Combination agent | Phase | Tumor type | Clinical efficacy | PFS | OS | Safety | Clinical trial | Status |
---|---|---|---|---|---|---|---|---|---|---|
VISTA | JNJ-61610588 | – | Phase1 | Advanced cancer | – | – | – | – | NCT02671955 | Terminated |
CI-8993 | – | Phase1 | Solid tumor | – | – | – | – | NCT04475523 | Recruiting | |
CA-170 | – | Phase 1 | Advanced solid tumors or lymphomas | Pharmacokinetics (PK) exposure with a t1/2 of 3.4 h for CA-170 | – | – | – | NCT02812875 | Completed | |
– | Phase 2 | Advanced solid tumors or lymphomas | ORR of 30% in Classical Hodgkin lymphoma, CBR of > 85% at a daily dose of 400 mg and PFS of 19.6 weeks in stage 4 non-squamous NSCLC | 19.6 weeks | – | – | – | – | ||
CD39 | TTX-030 | Pembrolizumab Docetaxel Gemcitabine nab-paclitaxel | Phase 1 | Solid tumor lymphoma | – | – | – | – | NCT03884556 | Active, not recruiting |
Budigalimab Docetaxel mFOLFOX6 Gemcitabine nab-paclitaxel Pembrolizumab | Phase 1 | Solid tumor, adult | – | – | – | – | NCT04306900 | Active, not recruiting | ||
SRF617 | Gemcitabine Albumin-Bound Paclitaxel Pembrolizumab | Phase 1 | Advanced solid tumor | – | – | – | – | NCT04336098 | Recruiting | |
CD73 | HLX23 | – | Phase 1 | Advanced solid tumor | – | – | – | – | NCT04797468 | Not yet recruiting |
LY3475070 | Pembrolizumab | Phase 1 | Advanced cancer | – | – | – | – | NCT04148937 | Active, not recruiting | |
AK119 | AK104 | Phase 1 | Advanced or metastatic solid tumors | – | – | – | – | NCT04572152 | Recruiting | |
CPI006 | Ciforadenant Pembrolizumab | Phase 1 | Advanced solid tumors | 1 patient (monotherapy) with metastatic CRPC: substantial reduction in the size of a target lesion after only 5 cycles, sustained at the time of cutoff | – | – | No DLTs reported* | NCT03454451 | Recruiting | |
Sym024 | Sym021 | Phase 1 | Metastatic cancer solid tumor | – | – | – | – | NCT04672434 | Recruiting | |
NZV930 | KAZ954 PDR001 NIR178 | Early Phase 1 | Solid tumors | – | – | – | – | NCT04237649 | Recruiting | |
PDR001 NIR178 | Phase 1 | NSCLC TNBC PDAC MSS colorectal cancer ovarian cancer RCC mCRPC | – | – | – | – | NCT03549000 | Recruiting | ||
MEDI9447 (Oleclumab) | Osimertinib AZD4635 | Phase 1 Phase 2 | Carcinoma, NSCLC | – | – | – | – | NCT03381274 | Active, not recruiting | |
Durvalumab | Phase 1 | Muscle-invasive bladder cancer | – | – | – | – | NCT03773666 | Active, not recruiting | ||
Paclitaxel Carboplatin MEDI4736 | Phase 1 Phase 2 | TNBC | – | – | – | – | NCT03616886 | Active, not recruiting | ||
Durvalumab Tremelimumab MEDI 0562 | Phase 2 | Ovarian cancer | – | – | – | – | NCT03267589 | Completed | ||
AZD4635 Durvalumab | Phase 2 | Prostate cancer mCRPC | Experimental group (n = 21): ORR 0.0%; positive control group (n = 20): ORR 5.0%* | rPFS 11.1 months for experimental group against 8.8 months for positive control group | Experimental group: NA; Positive control group: 10.72 months | Serious adverse events were 8/30 for experimental group, and 6/29 for control group | NCT04089553 | Active, not recruiting | ||
Durvalumab | Phase 2 | Luminal B | – | – | – | – | NCT03875573 | Recruiting | ||
Durvalumab Monalizumab | Phase 2 | Stage III NSCLC | – | – | – | – | NCT03822351 | Active, not recruiting | ||
CD38 | CID-103 | – | Phase 1 | Multiple myeloma | – | – | – | – | NCT04758767 | Recruiting |
Daratumumab | – | Phase 2 | Multiple myeloma | – | – | – | – | NCT04656951 | Recruiting | |
– | Phase 1 Phase 2 | GBM | – | – | – | – | NCT04922723 | Not yet recruiting | ||
– | Phase 2 | Multiple myeloma in relapse | – | – | – | – | NCT03697629 | Completed | ||
– | Phase 2 | Plasma cell myeloma | – | – | – | No report | NCT02944565 | Completed | ||
Phase 2 | Relapsed or refractory natural killer/T cell lymphoma | ORR 25.0%, CR 3.1%* | 53.0 days | 141.0 days | Serious adverse events: 17/32 | NCT02927925 | Completed | |||
– | Phase 2 | Myeloma multiple | – | – | – | – | NCT03992170 | Recruiting | ||
– | Phase 2 | Monoclonal gammopathy smoldering multiple myeloma | – | – | – | – | NCT03236428 | Active, not recruiting | ||
– | Phase 4 | Multiple myeloma | – | – | – | – | NCT03768960 | Active, not recruiting | ||
– | Phase 2 | Refractory T cell lymphoma relapsed T cell lymphoma | – | – | – | – | NCT04251065 | Active, not recruiting | ||
Nivolumab Cyclophosphamide | Phase 2 | Myeloma | – | – | – | – | NCT03184194 | Active, not recruiting | ||
– | Phase 2 | Multiple myeloma | – | – | – | – | NCT04230031 | Withdraw | ||
Thalidomide and Dexamethasone | Phase 2 | Relapse and/or refractory myeloma | – | – | – | NCT03143036 | Unknown | |||
Velcade, melphalan, and prednisone | Phase 3 | Multiple myeloma | The Kaplan–Meier estimate of the 36-month rate of OS was 78.0% (95% CI 73.2–82.0) in the D-VMP group and 67.9% (62.6–72.6) in the VMP group. PFS remained prominently improved for the D-VMP group (HR 0·42 [0·34–0·51]; p < 0·0001)* | – | – | Respiratory infections (54 of 278 patients had upper respiratory tract infections; 42 had bronchitis, and 34 had viral upper respiratory tract infections), cough (34), and diarrhea (28) | NCT02195479 (ALCYONE) | Active, not recruiting | ||
Lenalidomide and Dexamethasone | Phase 3 | Multiple myeloma | mPFS was not reached (95% CI 54.8–not reached) in the patients with Rd compared with 34.4 months (29.6–39.2) in the control group* | NA;34.4 months* | NA | Serious adverse events occurred in 281 (77%) patients with DRd and 257 (70%) patients with Rd. Thirteen (4%) patients with DRd and ten (3%) patients with Rd underwent TRDs | NCT02252172 (MAIA) | Active, not recruiting | ||
Bortezomib, Thalidomide, and Dexamethasone | Phase 3 | Multiple myeloma | 157 of 543 patients in the D-VTd group and 110 of 542 patients in the VTd group had achieved a stringent CR; CR was 211 vs 141, and 346 of 543 versus 236 of 542 achieved minimal residual disease negativity* | – | – | 46 deaths in the study were observed, and the most common grade 3 or 4 adverse events were neutropenia, lymphopenia, and stomatitis | NCT02541383 (VELCADE) | Active, not recruiting | ||
MOR03087 (MOR202) | Dexamethasone Pomalidomide Lenalidomide | Phase 1 Phase 2 | Multiple myeloma | ORR 0.0% for MOR03087 Biweekly Dose Escalation and MOR03087 Weekly Dose Escalation, 27.8% for MOR03087 Plus Dexamethasone, 47.6% for MOR03087 Plus Pomalidomide + Dexamethasone, 64.7% for MOR03087 Plus Lenalidomide + Dexamethasone | In the given order, 1.1, 2.1, 8.4, 15.9, 26.7(months) | – | In the given order, serious adverse events: 13/31, 4/4, 7/18, 20/21, 14/17 | NCT01421186 | Completed | |
Isatuximab | – | Phase 2 | Relapsed multiple myeloma refractory multiple myeloma | – | – | – | – | NCT04802031 | Withdraw | |
Lenalidomide, Bortezomib, and Dexamethasone | Phase 3 | Transplant-eligible NDMM | Minimal residual disease (MRD) negative rate after induction therapy was 35.6% in the RVd group and 50.1% in the isatuximab–RVD group. The CR rate after induction therapy was 24.2% in the isatuximab–RVD group and 21.6% in the RVd group | – | – | At least one AE of grade 3 or higher occurred in 63.6% of patients in the isatuximab–RVD group and 61.3% in the RVd group, respectively. The incidence of serious AEs was 34.8% and 36.3% | GMMG-HD7 | – | ||
Carfilzomib and Dexamethasone | Phase 3 | Relapsed multiple myeloma | mPFS was not reached in the isatuximab group compared with 19.15 months in the control group, with an HR of 0.53* | – | – | TEAEs of grade 3 or worse occurred in 136 of 177 patients in the isatuximab group versus 82 of 122 in the control group, serious TEAEs occurred in 105 versus 70 patients, and deaths were reported in six versus four patients | NCT03275285 | Active, not recruiting | ||
Pomalidomide and Dexamethasone | Phase 3 | Relapsed and refractory multiple myeloma | mPFS was 11.5 months (95% CI 8.9–13.9) in the isatuximab group, compared with 65 months (4.5–8.3) in the control group | 11.5 months; 65 months* | – | Infusion reactions (56), upper respiratory tract infections (69), and diarrhea (68). Serious adverse events were reported in 12 patients (8%) in the isatuximab group and 14 (9%) in the control group | NCT02990338 | Active, not recruiting | ||
Dexamethasone | Phase 2 | Relapsed multiple myeloma | – | – | – | – | NCT04965155 | Active, not recruiting | ||
– | Phase 2 | Multiple myeloma | – | – | – | – | NCT04786028 | Recruiting | ||
CellProtect | Phase 2 | Multiple myeloma | – | – | – | – | NCT04558931 | Recruiting | ||
– | Phase 2 | Smoldering plasma cell myeloma | – | – | – | – | NCT02960555 | Recruiting | ||
Bortezomib Dexamethasone | Phase 1 | Multiple myeloma | – | – | – | – | NCT04912427 | Recruiting | ||
– | Phase 1 | Plasma cell myeloma | MR 3.1%, SD 53.1% | 1.6 | 10.7 | 16 (50.0%) patients had Grade ≥ 3 TEAE* | NCT02514668 | Completed | ||
– | Phase 1 Phase 2 | Multiple myeloma | ORR 36.4%*, CBR 54.5% | 4.7 | – | No DLTs reported*. TEAEs of grade ≥ 3 included pneumonia in two patients, and intervertebral discitis, lung infection, disseminated intravascular coagulation, seizure, thrombotic cerebral infarction, ileus, and synovial cyst in one patient each | NCT02812706 | Active, not recruiting | ||
Cemiplimab | Phase 2 | Natural killer/T cell lymphoma relapsed natural killer/T cell lymphoma refractory natural killer/T cell lymphoma | – | – | – | – | NCT04763616 | Recruiting | ||
Carfilzomib Pomalidomide | Phase 2 | Recurrent plasma cell myeloma refractory plasma cell myeloma | – | – | – | – | NCT04850599 | Recruiting | ||
– | Phase 1 | Multiple myeloma | – | – | – | – | NCT03733717 | Active, not recruiting | ||
ISB 1342 | – | Phase 1 | Relapsed/refractory multiple myeloma | – | – | – | – | NCT03309111 | Recruiting | |
GEN3014 | – | Phase 1 Phase 2 | Multiple myeloma | – | – | – | – | NCT04824794 | Recruiting |
Clinical trials on CD73, CD39, and CD38 (Table 2)
-
In the phase III study of MAIA (NCT02252172), Scientists enrolled 737 patients with MM not appropriate for NDMM transplantation and divided them into two groups: one group receiving Lenalidomide and Dexamethasone (Rd, 369), the other receiving Daratumumab, Lenalidomide, and Dexamethasone (DRd, 368). At a median follow-up of 56.2 months (IQR 52.7–59.9), mPFS was not reached (95% CI 54.8–not reached) in the patients with Rd compared with 34.4 months (29.6–39.2) in the control group (HR 0.53 [95% CI 0.43–0.66]; p < 0.0001), the two groups did not reach mOS either (HR = 0.68, p = 0.0013). The most common (> 15%) grade 3 or higher treatment-emergent adverse events included neutropenia, pneumonia, anemia, and lymphopenia. Serious adverse events occurred in 281 (77%) patients with DRd and 257 (70%) patients with Rd. Thirteen (4%) patients with DRd and ten (3%) patients with Rd underwent TRDs [84].
-
Another phase III study is about ALCYONE (NCT02195479). Seven hundred and six patients with MM were enrolled, 356 received Velcade, Melphalan, and Prednisone (VMP), and the rest received Daratumumab, Velcade, Melphalan, and Prednisone (D-VMP). The HR for death in the D-VMP group compared with the VMP group was 0.60 (95% CI 0.46–0.80; p = 0.0003). The Kaplan–Meier estimate of the 36-month rate of OS was 78.0% (95% CI 73.2–82.0) in the D-VMP group and 67.9% (62.6–72.6) in the VMP group. PFS remained prominently improved for the D-VMP group (HR 0·42 [0·34–0·51]; p < 0·0001). The most frequent adverse events during maintenance of Daratumumab monotherapy in patients in the D-VMP group were respiratory infections (54 of 278 patients had upper respiratory tract infections; 42 had bronchitis, and 34 had viral upper respiratory tract infections), cough (34), and diarrhea (28) [85].
-
CASSIOPEIA is a phase III study showing the clinical benefit of Daratumumab combined with bortezomib, thalidomide, and dexamethasone (VTd) in transplant-eligible patients with MM (NCT02541383). Totally 1085 patients were enrolled and randomly assigned D-VTd (n = 543) or VTd (n = 542). The result showed that 100 days after transplantation, 157 of 543 patients in the D-VTd group and 110 of 542 patients in the VTd group had achieved a stringent CR (odds ratio 1.60, 95% CI 1.21–2.12, p = 0.0010). CR was 211 vs 141, and 346 of 543 versus 236 of 542 achieved minimal residual disease negativity (p < 0·0001). The two groups did not achieve mPFS either. Forty-six deaths in the study were observed (14 vs 32, 0.43, 95% CI 0.23–0.80), and the most common grade 3 or 4 adverse events were neutropenia, lymphopenia, and stomatitis [86]. The CASSIOPEIA study showed that compared with VTd, D-VTD showed a better and long-lasting efficacy. At the same time, the safety did not differ, making it an excellent benefit for MM patients capable of transplantation.
-
In a phase III study (NCT02990338), scientists enrolled 307 patients with relapsed and refractory multiple myeloma and then randomly assigned them to treatment: 154 to Isatuximab–pomalidomide–dexamethasone and 153 to pomalidomide–dexamethasone. At a median follow-up of 11.6 months (IQR 10.1–13.9), mPFS was 11.5 months (95% CI 8.9–13.9) in the Isatuximab group, compared with 65 months (4.5–8.3) in the control group (HR 0.596, 95% CI 0.44–0.81; p = 0.001). The most frequent treatment-emergent adverse events were infusion reactions (56), upper respiratory tract infections (69), and diarrhea (68). Serious adverse events were reported in 12 patients (8%) in the Isatuximab group and 14 (9%) in the control group. One case in the Isatuximab group (sepsis) and two in the control group (pneumonia and urinary tract infection) reported deaths [87].
-
IKEMA is a phase III study showing the efficacy of Isatuximab plus carfilzomib–dexamethasone versus carfilzomib–dexamethasone in patients with relapsed multiple myeloma (NCT03275285). Three hundred and two patients were enrolled: 179 were randomly assigned to the Isatuximab group and 123 to the control group. The result showed that mPFS was not reached in the Isatuximab group compared with 19.15 months (95% CI 15.77–not reached) in the control group, with an HR of 0.53 (99% CI 0.32–0.89; one-sided p = 0.0007). TEAEs of grade 3 or worse occurred in 136 of 177 patients in the Isatuximab group versus 82 of 122 in the control group, serious TEAEs occurred in 105 versus 70 patients, and deaths were reported in six versus four patients [88].
-
GMMG-HD7 is a phase III study showing the clinical benefit of Isatuximab in combination with lenalidomide, bortezomib, and dexamethasone (isatuximab–RVD) in patients with transplant-eligible NDMM. The minimal residual disease (MRD) negative rate after induction therapy was 35.6% in the RVd group and 50.1% in the isatuximab–RVD group. The CR rate after induction therapy was 24.2% in the isatuximab–RVD group and 21.6% in the RVd group. Regarding safety, at least one AE of grade 3 or higher occurred in 63.6% of patients in the isatuximab–RVD group and 61.3% in the RVd group, respectively. The incidence of serious AEs was 34.8% and 36.3%, respectively, and a comparable number of patients discontinued induction therapy because of AEs in the two groups. Isatuximab–RVd combination regimen can be used as the optimal regimen for NDMM patients undergoing transplantation, which has a good application prospect.
-
In the study (NCT02927925), 32 participants were enrolled. Everyone received Daratumumab 16 mg/kg by IV infusion to assess Daratumumab's clinical efficacy and safety in relapsed or refractory natural killer/T cell lymphomas (NKTCL). Fortunately, the primary outcome ORR of Daratumumab monotherapy was 25.0% of the total 32 Asian patients, no patient achieved CR, six patients had SD and 14 cases underwent PD, and PFS reached 53.0 days, while OS comes to 141.0 days. The median duration of response of the eight responders was 55.0 days [89]. There are 17 out of 32 participants who suffered severe adverse events, including pyrexia (5 cases), thrombocytopenia (3 cases), septic shock (3 cases), etc.
-
There are 19 clinical trials on CD73 on Clinicaltrials.gov, among which MEDI9447 (Oleclumab) is a human monoclonal antibody targeting CD73. In a phase II study (NCT04089553), researchers applied it as a combination therapy with AZD4635 or Durvalumab in patients with mCRPC who progressed on standard treatments. Among the 59 participants, 29 (Module 1) received monotherapy of AZD4635. The rest 30 patients (Module 2) received combination therapy of AZD4635 and Oleclumab. ORR is 5.0% in Module 1 and 0 in Module 2, respectively. The percentage of participants with prostate-specific antigen (PSA) is 3.6% and 3.3%, respectively. The percentage of participants with PFS at six months is 8.8% and 11.1% in Modules 1 and 2, respectively. The result indicated that Oleclumab has few benefits for patients with prostate cancer, and further studies are needed.
-
In another study (NCT04672434), researchers dug into Sym024, a newly developed anti-CD73 antibody, exploring Sym024’s safety and tolerance as monotherapy or in combination with Sym021 in patients suffering from solid tumor malignancies. However, no results have been posted either.
-
And TTX-030 is an uncompetitive allosteric inhibitor of CD39. By using an endpoint Malachite Green-based assay that detects the release of free phosphate (Pi), TTX-030 inhibited rhCD39-ECD ATPase activity with an IC50 of 0.20 ± 0.06 nM with 55% maximal inhibition (NCT03884556) [92]. In another study (NCT04306900), researchers combined TTX-030 with immunotherapy and chemotherapy like Budigalimab, Docetaxel, or Gemcitabine in patients suffering from solid tumors. The research was expected to improve the accumulation of pro-inflammatory ATP and immunosuppressive adenosine reduction, but the result has not been published.
-
CD39 and CD73, two ectonucleotidases, usually work together to upregulate the level of intercellular adenosine. Adenosine attaches to the A2A receptor to convey a signal repressing T cell activation [93]. Researchers tend to obstruct the two pathways for a better result. Although few studies are registered on Clinicaltrials.gov, we are inspired to see that many preclinical studies have taken place. In one study, researchers applied IPH5201 and IPH5301, which targeted CD39 and CD73, respectively, to mice with melanoma or colorectal cancer [94]. The result showed a decline in Ado accumulation and a limitation of Ado-mediated T cell inhibition. Overall, combinatory drug use needs more and more profound studies.
LAG-3
Structure and function
Clinical trials on LAG-3 (Table 3)
Target | Drug | Combination agent | Phase | Tumor type | Clinical efficacy | PFS (m) | OS (m) | Safety | Clinical trial | Status |
---|---|---|---|---|---|---|---|---|---|---|
LAG-3 | BMS 986,016(Relatlimab) | Nivolumab | Phase 2/3 | Melanoma | Researchers provided data on PFS*, ORR of the Relatlimab–Nivolumab group and the Nivolumab group was 43% and 33% | 10.12 for group: Relatlimab + Nivolumab, and 4.63 for group: Nivolumab* | NR for group: Relatlimab + Nivolumab, and 34 for group: Nivolumab | Serious adverse events were 108/355 for Group A: Relatlimab + Nivolumab, and 119/359 for Nivolumab | NCT03470922 (RELATIVITY-047) | Active, not recruiting |
Nivolumab | Phase 1 | Cancer | – | – | – | – | NCT02966548 | Active, not recruiting | ||
BMS-936558 | Phase 1 | Hematologic neoplasms | – | – | – | – | NCT02061761 | Active, not recruiting | ||
Nivolumab | Phase 2 | Melanoma | – | – | – | – | NCT03743766 | Recruiting | ||
Nivolumab, BMS-986213 | Phase 1 | Neoplasms by site | – | – | – | – | NCT01968109 | Active, not recruiting | ||
Phase 2 | ||||||||||
Nivolumab | Phase 2 | Metastatic uveal melanoma | – | – | – | – | NCT04552223 | Recruiting | ||
Nivolumab | Phase 1 | Glioblastoma | – | – | – | – | NCT03493932 | Active, not recruiting | ||
Nivolumab | Phase 2 | Chordoma, locally advanced chordoma, metastatic chordoma, unresectable chordoma | – | – | – | – | NCT03623854 | Recruiting | ||
Anti-PD-1 | Phase 1 | Glioblastoma | – | – | – | – | NCT02658981 | Active, not recruiting | ||
Anti-CD137 | Gliosarcoma, recurrent brain neoplasm | |||||||||
Elotuzumab, pomalidomide, dexamethasone | Phase 1 | Multiple myeloma | – | – | – | – | NCT04150965 | Recruiting | ||
Azacitidine Injection | Phase 2 | Acute myeloid leukemia | – | – | – | – | NCT04913922 | Recruiting | ||
Nivolumab | Phase 3 | Melanoma | – | – | – | – | NCT05002569 | Not yet recruiting | ||
Nivolumab | Phase 2 | Hepatocellular carcinoma, hepatoma | – | – | – | – | NCT04567615 | Recruiting | ||
Nivolumab | Phase 1 | Various advanced cancers | ORR 0 for HPV-positive SCCHN * | 3.81 | 8.84 | Serious adverse events included one case for angina pectoris, pathological fracture, pleural effusion, pulmonary hemorrhage, stridor each, two cases for malignant neoplasm, and three cases for dyspnea* | NCT02488759 | Active, not recruiting | ||
Nivolumab | Phase 1 | Advanced cancer | – | – | – | – | NCT03459222 | Recruiting | ||
Nivolumab | Phase 2 | Advanced cancer | – | – | – | – | NCT02996110 | Recruiting | ||
Nivolumab | Phase 1 | Hepatocellular carcinoma | – | – | – | – | NCT04658147 | Recruiting | ||
Nivolumab + Ipilimumab | Phase 2 | HNSCC | – | – | – | – | NCT04326257 | Recruiting | ||
Nivolumab | Phase 2 | MSS colorectal adenocarcinomas | – | – | – | – | NCT03642067 | Recruiting | ||
Nivolumab | Phase 2 | Refractory MSI-H solid tumors prior to PD-(L) 1 therapy | – | – | – | – | NCT03607890 | Recruiting | ||
Nivolumab | Phase 2 | HNSCC | – | – | – | – | NCT04080804 | Recruiting | ||
Nivolumab | Phase 2 | Advanced gastric cancer | – | – | – | – | NCT02935634 | Active, not recruiting | ||
Nivolumab, Carboplatin, Paclitaxel, Radiation | Phase 1 | Gastric cancer, esophageal cancer, gastroesophageal cancer | – | – | – | – | NCT03044613 | Active, not recruiting | ||
IMP321 (Eftilagimod Alpha) | Gemcitabine | Phase 1 | Pancreatic neoplasms | – | – | – | – | NCT00732082 | Terminated | |
Pembrolizumab | Phase 1 | Stage IV melanoma, stage III melanoma | 1/18 CR | – | – | No DLTs reported* | NCT02676869 | Completed | ||
Paclitaxel, Placebo | Phase 2 | Adenocarcinoma breast stage IV | – | – | – | – | NCT02614833 | Active, not recruiting | ||
– | Phase 1 | Advanced RCC | 7 of 8 patients treated with the higher doses of IM321 underwent SD at three months. 3 of 11 in the lower dose group did | – | – | No clinically significant local or systemic treatment-related adverse events were recorded. Along with the 195 adverse events, 20 (10%) were reported to be related to IMP321 and were grade 1 local reactions* | NCT00351949 (P003) | Completed | ||
Avelumab | Phase 1 | Solid tumors, peritoneal carcinomatosis | ORR 17% and DCR 33% with 1/6 PR, 1/6 SD, and 4/6 PD | – | – | No DLTs reported* | NCT03252938 | Recruiting | ||
Paclitaxel | Phase 1 | Metastatic breast cancer | ORR 50% and 1/10 PD | – | – | Six grade 3 adverse events were recorded, including asthenia (3 cases), neuropathy, allergic reaction, and neutropenia* | NCT00349934 | Completed | ||
Pembrolizumab | Phase 2 | NSCLC, HNSCC | ORR 47%* and DCR 82% with 8/17 PR and 6/17 SD | – | – | Most common toxicities included cough (31%), fatigue (19%), and diarrhea (15%) | NCT03625323 | Recruiting | ||
Pembrolizumab | Phase 2 | HNSCC | – | – | – | – | NCT04811027 | Not yet recruiting | ||
Paclitaxel | Phase 1 | Metastatic breast cancer | – | – | – | – | NCT04252768 | Not yet recruiting | ||
Immunological peptides and immunological adjuvants | Phase 1 | Melanoma | – | – | – | – | NCT00365937 | Terminated | ||
HLA-A2 peptides | Phase 2 | |||||||||
Montanide ISA-51 | ||||||||||
Melan-A VLP vaccine, cyclophosphamide, fludarabine phosphate | Phase 1 | Melanoma | – | – | – | Grade 3–4 treatment-related adverse events included anemia (16.6%), leucopenia (100%), thrombocytopenia (33%), febrile neutropenia (grade 3) (50%), CD4 lymphopenia (≥ grade 3) (100%) * | NCT00324623 | Completed | ||
Sym022 | – | Phase 1 | Metastatic cancer, solid tumor, lymphoma | 33.3% SD in group: Dose Level 3 | – | – | Serious adverse events were 1/3 in Dose Level 3(chest pain) and 2/6 in Dose Level 4 (gastrointestinal hemorrhage, sepsis, lipase increased, and tumor pain) * | NCT03489369 | Completed | |
Sym021 | Phase 1 | Metastatic cancer, solid tumor | – | – | – | – | NCT04641871 | Active, not recruiting | ||
Sym021 | Phase 1 | Metastatic cancer, solid tumor, lymphoma | – | – | – | – | NCT03311412 | Recruiting | ||
INCAGN02385 | – | Phase 1 | Cervical cancer, MSI-high endometrial cancer | – | – | – | – | NCT03538028 | Completed | |
INCAGN02390, INCMGA00012 | Phase 1/2 | Melanoma | – | – | – | – | NCT04370704 | Recruiting | ||
REGN3767 | – | Early Phase 1 | Large B cell lymphoma, DLBCL | – | – | – | – | NCT04566978 | Recruiting | |
Cemiplimab | Phase 1 | Malignancies | Monotherapy group: ORR 0% and DCR 48% with 12 SD Combination group: ORR 5% and DCR was 31% with 2 PR and 11 SD 2/12 PR and 6 SD in the group crossed over from monotherapy to the combination | – | – | 1/67 DLT in the combination group (G4 CK elevation + G3 myasthenic syndrome + G1 elevation of troponin* | NCT03005782 | Recruiting | ||
Cemiplimab | Phase 1/2 | Metastatic solid tumor | – | – | – | – | NCT04706715 | Not yet recruiting | ||
RO7247669 | – | Phase 1 | Solid tumors, metastatic melanoma, NSCLC, esophageal squamous cell carcinoma | – | – | – | – | NCT04140500 | Recruiting | |
RO7121661 | Phase 2 | Advanced or metastatic esophageal squamous cell carcinoma | – | – | – | – | NCT04785820 | Recruiting | ||
Atezolizumab | Phase 1 | Advanced liver cancers | – | – | – | – | NCT04524871 | Recruiting | ||
BI 754,091 | Anti-PD-1 | Phase1 | Advanced or metastatic solid tumors | – | – | – | 21/321 DLTs, particularly infusion-related reactions (n = 6). Serious AEs: 77/321 (27%): pleural effusion (n = 6), deep venous thrombosis (n = 4), cardiac tamponade (n = 1), and acute kidney injury (n = 1) | NCT03156114 | Active, not recruiting | |
Anti-PD-1 | Phase1 | NCT03433898 | Active, not recruiting | |||||||
Anti-PD-1 | Phase1 | NCT03780725 | Terminated | |||||||
Anti-PD-1 | Phase2 | NCT03697304 | Active, not recruiting | |||||||
EMB-02 | – | Phase 1 | Advanced solid tumors | NCT04618393 | Recruiting | |||||
LAG525 | PDR001 | Phase 2 | SCLC, gastric adenocarcinoma, esophageal adenocarcinoma, castration-resistant prostate adenocarcinoma, soft tissue sarcoma, ovarian adenocarcinoma, advanced well-differentiated neuroendocrine tumors | ORR 9.3%, DCR for neuroendocrine tumors (86%), diffuse large B cell lymphoma (43%), and small-cell lung cancer (27%)* | 2.8 | – | 11/72 patients had grade 3 or 4 AEs including dyspnea, fatigue, and poor appetite | NCT03365791 | Completed | |
DLBCL | ||||||||||
Spartalizumab | Phase 2 | Triple-negative breast cancer | ORR for LAG525 + Spartalizumab (5.0), LAG525 + Spartalizumab + Carboplatin (32.4), LAG525 + Carboplatin (17.6)* | LAG525 + Spartalizumab (1.4), LAG525 + Spartalizumab + Carboplatin (4.3), LAG525 + Carboplatin (3.0) | – | Serious adverse events for LAG525 + Spartalizumab (6/19), LAG525 + Spartalizumab + Carboplatin (12/34), LAG525 + Carboplatin (14/34) | NCT03499899 | Completed | ||
PDR001 | Phase 1 | Advanced solid tumors | 11/121 patients in the combination group achieved PR 1 patient had a CR | – | – | DLTs occurred in 4/121 patients including grade 3 and 4 pneumonitis, acute kidney injury, and autoimmune hepatitis* | NCT02460224 | Completed | ||
Spartalizumab | Phase 1 | TNBC | – | – | – | – | NCT03742349 | Recruiting | ||
Spartalizumab | Phase 2 | Melanoma | – | – | – | – | NCT03484923 | Recruiting | ||
MGD013 | Alone or in combination with margetuximab (for patients who had expression of HER2 on their tumors) | Phase1 | Advanced or metastatic solid or hematologic malignancies | Dose escalation (n = 29): ORR 10% and DCR 55% with 3 confirmed PR, 1 unconfirmed PR, and 13 SD Expansion cohort (n = 41): ORR 7%, DCR 59% with 3 PR, and 21 SD | – | – | 2/207 DLTs: immune-mediated hepatitis and increased lipase* | NCT03219268 | Active, not recruiting | |
FS118 | Phase1 | Advanced solid tumors | – | – | – | – | NCT03440437 | Recruiting |
-
The first phase I trial using the dose-escalated IMP321 as monotherapy was conducted on 24 patients suffering from advanced metastatic renal cell carcinoma in 2006 (NCT00351949, P003). Patients with advanced RCC were treated with escalating doses of IMP321 s.c. Their blood samples were tested to detect human anti-IMP321 antibody formation and determine long-lived CD8 T cell responses. Although no therapy response was reported, 7 of 8 patients treated with the higher doses of IM321 underwent SD at three months. On the contrary, only 3 of 11 in the lower dose group did that (p = 0.015). No clinically significant local or systemic treatment-related adverse events were recorded. Along with the 195 adverse events, 20 (10%) were reported to be related to IMP321 and were grade 1 local reactions [107].
-
IMP321 has also been combined with first-line chemotherapy and immunotherapies in a series of clinical trials conducted in melanoma (NCT02676869, NCT01308294, NCT00324623), metastatic breast cancer (NCT00349934), and pancreatic neoplasms (NCT00732082). Many researchers have reported promising results of IMP321 in melanoma therapy, among which four studies have been reported on ClinicalTrials.gov.
-
So far, the safety and efficacy of Relatlimab administered alone and in combination with anti-PD-1 monoclonal antibody (Nivolumab, BMS-936558) were explored in advanced solid tumors in a phase I study (NCT02966548), no result reported.
-
In another study (NCT02488759), 578 participants were divided into six groups to investigate the safety and efficacy of Nivolumab combination therapy in virus-associated Tumors. in Metastatic Combo C (8 participants), everyone received Nivolumab 240 mg IV over 30 min + Relatlimab 80 mg IV over 60 min administered every two weeks for a maximum of 24 months. ORR is 0 for the 8 participants with HPV-positive SCCHN, PFS is 3.81 months, and OS is 8.84 months. Five out of 8 patients underwent severe adverse events, including one case for angina pectoris, pathological fracture, pleural effusion, pulmonary hemorrhage, stridor, two cases for malignant neoplasm, and three cases for dyspnea. However, the sample capacity is too small. It is insufficient to reach a firm conclusion.
-
Specifically, the primary endpoint mPFS of the Relatlimab–Nivolumab group was 10.1 months compared with 4.6 months of Nivolumab monotherapy (HR = 0.75). ASCO 2022 updated that the Relatlimab–Nivolumab group did not reach mOS while the mOS of Nivolumab was 34 m (HR = 0.81), which showed that patients treated with Relatlimab–Nivolumab had better survival, but it is not significant. And ORR of the Relatlimab–Nivolumab group and the Nivolumab group was 43% and 33%, respectively. All the subgroup analyses (including PD-L1 and LAG-3 expression, BRAF mutation status, M1c stage, higher tumor burden, higher LDH, etc.) favored Relatlimab–Nivolumab over Nivolumab, and ORR were higher in patients with LAG-3 ≥ 1% and PD-L1 ≥ 1%. Patients in the Relatlimab–Nivolumab group suffered more grade 3 or 4 treatment-related adverse events than those in the Nivolumab group (18.9% to 9.7%). Since the participants in the Relatlimab–Nivolumab group had a longer PFS, the implications of the adverse events occurrence rates need to be clarified. Besides, the treatment-related adverse events among the two groups did not show many differences, including hypothyroidism or thyroiditis, rash, and diarrhea or colitis [108].
IDO-1
Structure and function
Clinical trials on IDO-1 (Table 4)
Target | Drug | Combination agent | Phase | Tumor type | Clinical efficacy | PFS | OS | Safety | Clinical trial | Status |
---|---|---|---|---|---|---|---|---|---|---|
IDO-1 | Epacadostat (INCB24360) | – | Phase 1 | Rectal Cancer | – | – | – | – | NCT03516708 | Recruiting |
MEDI4736 | Phase 1 Phase 2 | Solid Tumors Head and Neck Cancer Lung Cancer UC | In the study, attendants were divided into 6 groups, ORR was 16.7%, 0.0%, 25.0%, 0.0%, 12.5%, 22.2% for each group; ORR 12.2% for attendants received Epacadostat (100 mg) + Durvalumab (10 mg/kg), and that was 12.9% for participants received Epacadostat (300 mg) + Durvalumab (10 mg/kg)* | 2.4, 12.0, 1.9, 1.7, 4.12.5 1.9 and 2.1 | – | Serious adverse events were 2/6, 0/3, 2/4, 0/4, 4/8, 3/9 for each group. Serious adverse events were 20/49, 54/93 for each group | NCT02318277 (ECHO-203) | Completed | ||
Pembrolizumab | Phase 3 | UC | Experimental group (n = 44): ORR 31.8%; positive control group (n = 49): ORR 24.5%* | – | – | Serious adverse events were 23/43 against 23/49 | NCT03361865 (KEYNOTE-672/ECHO-307) | Completed | ||
Pembrolizumab | Phase 1 Phase 2 | Advanced melanoma | – | – | – | – | NCT02178722 (ECHO-202/KEYNOTE-037) | Completed | ||
Fludarabine Cyclophosphamide | Phase 1 | Ovarian Cancer Fallopian Tube Carcinoma Primary Peritoneal Carcinoma | – | – | – | – | NCT02118285 | Completed | ||
Pembrolizumab | Phase 2 | Lung Cancer | Experimental group (n = 77): ORR 32.5%; control group (n = 77): ORR 39.0%* | Experimental group: 6.7; control group: 6.2 | NA | Serious adverse events were 23/75 for experimental group, and 29/77 for control group | NCT03322540 (KEYNOTE-654–05/ECHO-305–05) | Completed | ||
Pembrolizumab | Phase 2 | Thymic Carcinoma Thymus Neoplasms Thymus Cancer | 1/40 attendant had a complete response, 8/40 participants had partial response, 21/40 participants received stable disease, 10/40 participants suffered progression* | 4.2 | 24.9 | 2/40 patients suffered myocarditis, one case for hyperglycemia, hepatitis, bullous pemphigoid, and polymyositis each | NCT02364076 | Unknown | ||
Pembrolizumab Platinum-based chemotherapy | Phase 2 | Lung Cancer | Experimental group (n = 91): ORR 26.4%; control group (n = 87): ORR 44.8%* | Experimental group: 8.0; control group: 8.2 | NA | Serious adverse events were 47/90 against 41/86 | NCT03322566 (KEYNOTE-715–06/ECHO-306–06) | Completed | ||
Pembrolizumab | Phase 3 | UC | Experimental group (n = 42): ORR 21.4%; control group (n = 42): ORR 9.5%* | – | – | Serious adverse events were 22/42 for experimental group, and 16/41 for control group | NCT03374488 (KEYNOTE-698/ECHO-303) | Completed | ||
– | Phase 1 | Solid Tumors and Hematologic Malignancy | – | – | – | – | NCT01195311 | Completed | ||
Pembrolizumab | Phase 2 | Gastrointestinal Stromal Tumors | – | – | – | – | NCT03291054 | Completed | ||
Pembrolizumab Cetuximab Cisplatin Carboplatin 5-Fluorouracil | Phase 3 | Head and Neck Cancer | Experimental group (n = 35): ORR 31.4%; negative control group (n = 19): ORR 21.1%; positive control group (n = 35): ORR 34.3%* | – | Serious adverse events were 12/34 for experimental group, 8/19 for negative control group, and 12/34 for positive control group | NCT03358472 (KEYNOTE-669/ECHO-304) | Active, not recruiting | |||
Low dose cyclophosphamide | Phase 1 Phase 2 | Breast Cancer Female Breast Neoplasm Female | – | – | – | – | NCT03328026 | Recruiting | ||
BMS-986205 | Nivolumab | Phase 2 | Endometrial Adenocarcinoma and Endometrial Carcinosarcoma | – | – | – | – | NCT04106414 | Active, not recruiting | |
Nivolumab | Phase 3 | Melanoma Skin Cancer | – | – | – | Serious adverse events were 4/10 for experimental group against 4/10 for control group* | NCT03329846 | Completed | ||
Nivolumab | Phase 1 Phase 2 | Advanced Cancer | – | – | – | Two cases for malignant neoplasm progression, one case for tuberculosis, acute kidney injury, pneumonitis each | NCT03792750 | Completed | ||
– | Phase 1 | Cancer | – | – | – | – | NCT03247283 | Completed | ||
Nivolumab Gemcitabine Cisplatin Placebo | Phase 3 | Bladder Cancer Muscle-Invasive Bladder Cancer | – | – | – | – | NCT03661320 | Recruiting | ||
Itraconazole Rifampin | Phase 1 | Malignancies Multiple | – | – | – | – | NCT03346837 | Completed | ||
Nivolumab | Phase 1 | Advanced Cancer | – | – | – | – | NCT03192943 | Completed | ||
Nivolumab Ipilimumab | Phase 1 Phase 2 | Advanced Cancer Melanoma NSCLC | – | – | – | – | NCT02658890 | Recruiting | ||
CD27 | Varlilumab (CDX-1127) | – | Phase 1 Phase 2 | B Cell Lymphoma | – | – | – | – | NCT03307746 | Active, not recruiting |
nivolumab | Phase 1 Phase 2 | HNSCC Ovarian Carcinoma-Enrollment Completed CRC-Enrollment Completed RCC (Phase ll Only) GBM (Phase ll Only)-Enrollment Completed | – | – | – | – | NCT02335918 | Completed | ||
– | Phase 1 | Selected refractory or relapsed hematologic malignancies or solid tumors | A patient with mRCC underwent a partial response (78% shrinkage) and had a durable response with PFS > 2.3 years without additional treatment. Eight patients underwent SD > 3 months, including a patient with metastatic RCC with PFS of > 3.9 years | – | – | Only one case with grade 3 transient asymptomatic hyponatremia was reported. Other adverse events were limited to grade 1 or 2 in severity* | NCT01460134 | Completed | ||
Atezolizumab Cobimetinib | Phase 2 | Unresectable Liver and Intrahepatic Bile Duct Carcinoma | – | – | – | – | NCT04941287 | Recruiting | ||
ONT-10 | Phase 1 | Advanced Breast Carcinoma Advanced Ovarian Carcinoma | – | – | – | – | NCT02270372 | Completed | ||
Rituximab | Phase 2 | Relapsed or refractory B cell malignancies | – | – | – | Three Grade 3 treatment-related events in the study, including hyponatremia, decreased appetite, and decreased lymphocyte count | ISRCTN15025004 | Ongoing | ||
Atezolizumab | Phase 1 | Refractory NSCLC Stage IV Lung Cancer AJCC v8 | – | – | – | – | NCT04081688 | Recruiting | ||
IMA950 poly-ICLC | Phase 1 | Glioma Malignant Glioma Astrocytoma, Grade II Oligodendroglioma Glioma, Astrocytic Oligoastrocytoma, Mixed | – | – | – | – | NCT02924038 | Active, not recruiting | ||
MHP Montanide ISA-51 poly-ICLC | Phase 1 Phase 2 | Melanoma | – | – | – | – | NCT03617328 | Recruiting |
-
In phase I and II studies, for example, ECHO-202/KEYNOTE-037 (NCT02178722), the result indicated excellent tolerance and efficacy of combination therapy, including Epacadostat plus Pembrolizumab that targets advanced melanoma. However, in a phase III study, the combination of Epacadostat and Pembrolizumab showed no superiority over Pembrolizumab monotherapy. Hence, scientists try to resolve this by exploring the efficacy of Epacadostat in other solid tumors. In KEYNOTE-672/ECHO-307 (NCT03361865), another phase III study, Epacadostat, along with Pembrolizumab, was applied to patients with urothelial cancer (UC). Participants were given Pembrolizumab 200 mg intravenously, while one group (44 participants) received Epacadostat 100 mg BID orally twice daily, and the other (49 participants) took a placebo instead. The result showed that patients in the Pembrolizumab + Epacadostat group had an ORR of 31.8%, compared to 24.5% in the Pembrolizumab + Placebo group. Twenty-three out of 43 patients and 23 out of 49 reported severe adverse events. It is promising news that Epacadostat did improve the therapy, but further studies are needed to explore its effect on tolerance.
-
A phase II clinical trial about the combined therapy of Epacadostat plus Pembrolizumab in patients suffering advanced solid tumors showed an encouraging anti-tumor response (NCT03322540).
-
A study (NCT03792750) concerning advanced tumors in Chinese where BMS-986205 was combined with Nivolumab. Twelve participants were enrolled, 11 experienced adverse events, 3 underwent severe adverse events, and 5 discontinued due to experiencing adverse events. There were two cases of malignant neoplasm progression and one of tuberculosis, acute kidney injury, and pneumonitis.
-
In one study (NCT03329846), researchers enrolled 20 patients suffering from melanoma and skin cancer to investigate the safety of combination therapy of BMS-986205 with Nivolumab compared to Nivolumab only. The result showed that four patients underwent severe adverse events in both groups. The study has been completed, and the outcome indicated that BMS-986205 has little effect on tolerance. However, this phase III study intended to enroll 700 participants and ended up reporting only 20 cases, and there were no other results reported either. These indicated a relatively unsuccessful study, and a more extensive sample study is needed to add to the stringency.
CD27
Structure and function
Clinical trials on CD27 (Table 4)
-
In phase I clinical trial exploring the safety and pharmacokinetics of CDX-1127 in patients suffering from selected refractory or relapsed hematologic malignancies or solid tumors (NCT01460134). Fifty-six patients participated in the study until March 2014. In a 3 + 3 dose escalation design (n = 25), the patients received a single dose of Varlilumab (0.1, 0.3, 1.0, 3.0, or 10 mg/kg IV) to determine an applicable dose. Base on the data of dose escalation cohort, expansion cohorts were initiated at 3.0 mg/kg in patients with melanoma (n = 16) and RCC (n = 15). After only one cycle of Varlilumab treatment, a patient with metastatic RCC underwent a partial response (78% shrinkage) and had a durable response with PFS > 2.3 years without additional treatment. Eight patients underwent SD > 3 months, including a patient with metastatic RCC with PFS of > 3.9 years. Only one case with grade 3 transient asymptomatic hyponatremia was reported. Other adverse events were limited to grade 1 or 2 in severity. The study confirmed that at 10 mg/kg, Varlilumab showed a good tolerance, while the maximum tolerated dose remains unknown, and Varlilumab has clinical activity. Since two RCC patients had extremely long PFS, and the recruitment of 90 has been completed, we expect the ITT group's analysis and further analysis, which show more favorable results for patients with RCC and other mechanisms [124].
-
In another phase II study, researchers focused on the cooperation of Rituximab and Varlilumab while applying to relapsed or refractory B cell malignancies (ISRCTN15025004), which demonstrated depleted B cells and increased infiltration of myeloid cells [125]. Forty patients suffering low- or high-grade relapsed or refractory CD20+ B cell lymphoma were enrolled. Participants were divided into two groups, receiving different doses of Varlilumab; the result has not come out yet, but researchers reported three Grade 3 treatment-related events in the study, including hyponatremia, decreased appetite, and decreased lymphocyte count [125].
-
Another study exploring the effect of Varlilumab and Nivolumab in advanced refractory solid tumors (NCT02335918) is completed nowadays, and the result is about to publicly available.
CD70
Clinical trials on CD70 (Table 5)
Target | Drug | Combination agent | Phase | Tumor type | Clinical efficacy | PFS | OS | Safety | Clinical trial | Status |
---|---|---|---|---|---|---|---|---|---|---|
TIM-3 | Sym023 | – | Phase 1 | Metastatic Cancer Solid Tumor Lymphoma | 3 patients were reported SD > 16 weeks, 7 were reported SD ≤ 16 weeks. ORR not reported | – | – | Researchers reported one case of immune-mediated arthritis for Sym023 0.1 mg/kg, one case of lipase increased and pathological fracture each for 10.0 mg/kg, and one case of back pain plus spinal cord compression for 20.0 mg/kg* | NCT03489343 | Completed |
Sym021 Sym022 | Phase 1 | Metastatic Cancer Solid Tumor | – | – | – | – | NCT04641871 | Recruiting | ||
Sym021 Sym022 | Phase 1 | Metastatic Cancer Solid Tumor Lymphoma | – | – | – | – | NCT03311412 | Completed | ||
MBG453 (Sabatolimab) | Venetoclax Azacitidine | Phase 2 | Acute Myeloid Leukemia | – | – | – | – | NCT04150029 | Recruiting | |
Azacitidine | Phase 3 | MDS Leukemia Myelomonocytic Chronic | – | – | – | – | NCT04266301 | Active, not recruiting | ||
Hypomethylating agents | Phase 2 | MDS | – | – | – | – | NCT03946670 | Active, not recruiting | ||
HDM201 Venetoclax | Phase 1 | AML High-risk MDS | – | – | – | – | NCT03940352 | Recruiting | ||
PDR001 Decitabine | Phase 1 Phase 2 | Advanced Malignancies | ORR in the monotherapy group was 0% and DCR was 29% with 25/87 SD* ORR in the combination group was 5% and DCR was 44% with 4/86 PR and 34/86 SD* | – | – | One DLT in combination cohort (grade 4 MG)* 11% developed grade 3 or 4 AEs in the combination cohort* | NCT02608268 | Active, not recruiting | ||
– | Phase 1 | GBM | – | – | – | – | NCT03961971 | Recruiting | ||
Azacitidine Decitabine INQOVI (oral decitabine) | Phase 2 | MDS | – | – | – | – | NCT04878432 | Recruiting | ||
Sabatolimab Azacitidine | Phase 1 Phase 2 | Acute Myeloid Leukemia | – | – | – | – | NCT04623216 | Recruiting | ||
NIS793 canakinumab | Phase 1 | MDS | – | – | – | – | NCT04810611 | Recruiting | ||
Sabatolimab, azacitidine, venetoclax | Phase 2 | MDS | – | – | – | – | NCT04812548 | Recruiting | ||
TSR-022 | TSR-042 | Phase 2 | Adult Primary Liver Cancer Advanced Adult Primary Liver Cancer Localized Unresectable Adult Primary Liver Cancer | – | – | – | – | NCT03680508 | Recruiting | |
TSR-042 | Phase 2 | Melanoma Stage III Melanoma Stage IV | – | – | – | – | NCT04139902 | Recruiting | ||
– | Phase1 | Advanced solid tumors | – | – | – | – | NCT02817633 | Recruiting | ||
RO7121661 | – | Phase 1 | Solid Tumors Metastatic Melanoma NSCLC SCLC ESCC | – | – | – | – | NCT03708328 | Active, not recruiting | |
RO7247669 Nivolumab | Phase 2 | Advanced or Metastatic ESCC | – | – | – | – | NCT04785820 | Recruiting | ||
LY3321367 | LY3300054 | Phase 1 | Solid Tumor | In monotherapy expansion cohort, outcomes varied: anti-PD-1/L1 refractory patients [N = 23, ORR 0%, DCR 35%, PFS 1.9 months] versus anti-PD-1/L1 responders (N = 14, ORR 7%, DCR 50%, PFS 7.3 months). In combination expansion cohorts (N = 91), ORR and DCR were 4% and 42% | 1.9, 7.3(detailed in Clinical efficacy) | – | No DLTs were observed*, treatment-related adverse events (≥ 2 patients) included pruritus, rash, fatigue, anorexia, and infusion-related reactions | NCT03099109 | Active, not recruiting | |
LY3300054 Ramucirumab Abemaciclib Merestinib | Phase 1 | Solid Tumor MSI-H Solid Tumors Cutaneous Melanoma Pancreatic Cancer Breast Cancer (HR + HER2-) | – | – | – | DLTs associated with hepatotoxicity were observed in 3 of 4 patients in the abemaciclib lead-in cohorts. No DLTs or grade 3 or 4 hepatotoxicity were reported in the concurrent abemaciclib arm* | NCT02791334 | Active, not recruiting | ||
BTLA | JS004 | – | Phase 1 | Advanced Solid Tumors | – | – | – | – | NCT04773951 | Recruiting |
Toripalimab | Phase 1 Phase 2 | Advanced Lung Cancer | – | – | – | – | NCT05000684 | Recruiting | ||
– | Phase 1 Phase 2 | HNSCC Nasopharyngeal Carcinoma | – | – | – | – | NCT04929080 | Recruiting | ||
– | Phase 1 | Recurrent/Refractory Malignant Lymphoma | – | – | – | – | NCT04477772 | Recruiting | ||
– | Phase 1 | Advanced Solid Tumor | – | – | – | – | NCT04278859 | Unknown | ||
Toripalimab | Phase 1 | Advanced Unresectable Solid Tumor Metastatic Solid Tumor | – | – | – | – | NCT04137900 | Recruiting | ||
Toripalimab | Phase 1 | Advanced Unresectable Solid Tumor Metastatic Solid Tumor | – | – | – | – | NCT04137900 | Recruiting | ||
CD47 | Magrolimab (Hu5F9-G4) | Phase 1 | Solid tumors | ORR ~ 5% DCR 19% with 2/43 PR (ovarian and fallopian tube cancers) and 6/43 SD (CRC)* | – | – | AEs occurred with higher doses. These included constitutional symptoms (50%), headache (34%), anemia (39%), and lymphopenia (28%) * | NCT02216409 | Completed | |
Rituximab Gemcitabine Oxaliplatin | Phase 1 Phase 2 | Non-Hodgkin Lymphoma | CRR 21% ORR 49% with 16/75 CR and 21/75 PR | – | – | DLTs 4% (no specifics provided) * | NCT02953509 | Active, not recruiting | ||
Venetoclax Azacitidine Cytarabine Daunorubicin Idarubicin Steroidal Eye Drops | Phase 3 | AML | – | – | – | – | NCT04778397 | Recruiting | ||
AK117 | – | Phase 1 | Neoplasms Malignant | – | – | – | – | NCT04728334 | Recruiting | |
Azacitidine | Phase 1 Phase 2 | Myelodysplastic Syndrome | – | – | – | – | NCT04900350 | Recruiting | ||
Azacitidine | Phase 1 Phase 2 | Acute Myeloid Leukemia | – | – | – | – | NCT04980885 | Recruiting | ||
Phase 1 | Neoplasms Malignant | – | – | – | – | NCT04349969 | Not yet recruiting | |||
AK112 Nab-paclitaxel paclitaxel | Phase 2 | Metastatic Triple-negative Breast Cancer Locally Advanced Triple-negative Breast Cancer | – | – | – | – | NCT05227664 | Recruiting | ||
Capecitabine tablets Oxaliplatin Cisplatin Paclitaxel Irinotecan Docetaxel 5-FU AK104 | Phase 1 Phase 2 | Advanced Malignant Tumors | – | – | – | – | NCT05235542 | Not yet recruiting | ||
TTI-622 | – | Phase 1 | Relapsed or refractory lymphomas | 1 patient (DLBCL) with 5 prior lines of therapy achieved a PR by week 8 and a CR by week 36 | – | – | No DLTs* | NCT03530683 (TTI-622–01) | Recruiting | |
RRx-001 | Nivolumab | Phase 1 | Advanced solid malignancies or lymphomas | ORR 25%, DCR 67% with 3/12 PR, 5/12 SD, and 3/12 PD | – | – | No DLTs reported 1 patient discontinued therapy due to pneumonitis* | NCT02518958 (PRIMETIME) | Completed | |
B7-H3 | MGC018 | MGA012 | Phase 1 Phase 2 | Advanced Solid Tumor, Adult Metastatic Castrate Resistant Prostate Cancer NSCLC TNBC HNSCC Melanoma Prostate Cancer | ORR 0% and DCR 15% with 3/20 SD | – | – | 1 DLT: grade 4 neutropenia 3 serious AEs: pneumonitis, gastroenteritis, stasis dermatitis* | NCT03729596 | Recruiting |
B7-H3 CAR-T | Temozolomide | Phase 1 | Recurrent GBM Refractory GBM | – | – | – | – | NCT04385173 | Unknown | |
Temozolomide | Phase 1 Phase 2 | Recurrent GBM Refractory GBM | – | – | – | – | NCT04077866 | Recruiting | ||
– | Phase 1 | Lung Cancer Immunotherapy CAR-T Cell | – | – | – | – | NCT03198052 | Recruiting | ||
Fludarabine Cyclophosphamide | Phase 1 | Epithelial Ovarian Cancer | – | – | – | – | NCT04670068 | Recruiting | ||
– | Early Phase 1 | Osteosarcoma Neuroblastoma Gastric Cancer Lung Cancer | – | – | – | – | NCT04864821 | Not yet recruiting | ||
– | Phase 1 Phase 2 | Solid Tumor | – | – | – | – | NCT04432649 | Recruiting | ||
GD2, PSMA CAR-T cells | Phase 1 Phase 2 | Neuroblastoma | – | – | – | – | NCT04637503 | Recruiting | ||
Enoblituzumab (MGA271) | – | Phase 1 | Neuroblastoma Rhabdomyosarcoma Osteosarcoma Ewing Sarcoma Wilms Tumor Desmoplastic Small Round Cell Tumor | – | – | – | – | NCT02982941 | Completed | |
Ipilimumab | Phase 1 | Melanoma NSCLC | – | – | – | – | NCT02381314 | Completed | ||
– | Phase 2 | Prostate Cancer | 31% of patients had a more than 10% decline in PSA before post-prostatectomy, and an altered Gleason score was observed* | – | – | 3 cases of serious adverse events*, including ascites, pericardial effusion, cardiac disorders, atrial fibrillation, pericarditis, myocarditis, and infusion-related reaction | NCT02923180 | Active, not recruiting | ||
Retifanlimab Tebotelimab | Phase 2 | Head and Neck Cancer Head and Neck Neoplasms HNSCC | – | – | – | – | NCT04634825 | Recruiting | ||
IP FT516 IL-2 | Phase 1 | Ovarian Cancer Fallopian Tube Adenocarcinoma Primary Peritoneal Cavity Cancer | – | – | – | – | NCT04630769 | Completed | ||
Pembrolizumab MGA012 | Phase 1 | Melanoma Head and Neck Cancer NSCLC UC | ORR 33.3% for patients with CPI-naïve HNSCC, and 35.7% for patients with CPI-naïve NSCLC | – | – | Treatment-related adverse events occurred in 116 patients (87.2%) and were grade ≥ 3 in 28.6%* | NCT02475213 | Completed | ||
B7-H4 | FPA150 | – | Phase 1 | B7-H4 positive solid malignancies | ORR 3% and DCR 38% with 1/29 PR and 10/29 SD | – | – | No DLTs or grade 4/5 toxicities were reported | NCT03514121 | Completed |
CD70 | SGN-CD70A | – | Phase 1 | CD70-positive metastatic RCC | One patient in the 50-μg/kg cohort achieved a PR (6%), and 13 out of 18 patients (72%) had SD. Thus, the overall disease control rate was 78%, and the estimated median PFS was 3.5 months | 3.5 months | – | Grade 3 TEAEs were thrombocytopenia (22%), anemia (17%), neutropenia (17%), and dehydration (11%)* | NCT02216890 | Completed |
Cusatuzumab | Azacitidine and Venetoclax | Phase 1 | AML | – | – | – | – | NCT04150887 | Active, not recruiting | |
TIGIT | Tiragolumab | Atezolizumab | Phase 2 | NSCLC | ORR 31.3% in experimental group vs 16.4% in the control group* | 5.4 months vs 3.6 months* | – | 14 (21%) patients receiving combination therapy and 12 (18%) patients receiving monotherapy had serious adverse effects, two treatment-related deaths | NCT03563716 | Active, not recruiting |
Atezolizumab | Phase 3 | NSCLC | – | – | – | – | NCT04294810 (SKYSCRAPER-01) | Recruiting | ||
Atezolizumab, Carboplatin and Etoposide | Phase 3 | ES-SCLC | – | 5.4 months in the experimental group vs 5.6 months in the control group* | Both 13.6 months* | Grade 3/4 TRAEs occurred in 52.3% of the experimental group and 55.7% of the placebo group and Grade 5 TRAEs occurred in 0.4% of experimental group and 2.0% placebo group | NCT04256421 (SKYSCRAPER-02) | Active, not recruiting | ||
Etigilimab (OMP-313M32) | Nivolumab | Phase 1 | Advanced or metastatic cancer | No DLT detected. The maximum administered dose was 20 mg/kg. Besides, in the phase Ia study, seven patients (30.0%) had SD, and no PR was reported; in the phase Ib study, one patient had a partial response. One patient had prolonged SD of nearly eight months | 56.0 days in phase 1a, 57.5 days in phase 1b | – | The most reported AEs were rash (43.5%), nausea (34.8%), and fatigue (30.4%) in phase Ia and decreased appetite (50.0%), nausea (50.0%), and rash (40%) in Phase Ib. Six patients experienced Grade ≥ 3 treatment-related AEs* | NCT03119428 | Terminated |
-
SGN-CD70A is a CD70-targeted antibody–drug conjugate. In a phase I trial on participants suffering CD70-positive, metastatic RCC (NCT02216890), 18 patients were enrolled, 94% had the clear cell subtype of RCC, and all participants received SGN-CD70A IV in dose escalation (8, 15, 30, 50, 80, 120, 160, and 200 μg/kg). One patient in the 50-μg/kg cohort achieved a PR (6%), and 13 out of 18 patients (72%) had SD. Thus, the overall disease control rate was 78%, and the estimated median PFS was 3.5 months [136]. Grade 3 TEAEs were thrombocytopenia (22%), anemia (17%), neutropenia (17%), and dehydration (11%), and there were no reports of neutropenic fever. The result did not support its development in mRCC, but there is still a chance in combination therapy.
-
In a phase I study, Cusatuzumab was applied with Azacitidine and Venetoclax to patients suffering AML (NCT04150887). Sixty-one participants were divided into two cohorts, receiving combination therapy of Cusatuzumab + Venetoclax, or Cusatuzumab + Venetoclax + Azacitidine. The study is not recruiting now, hoping it will bring us a satisfying outcome.
TIM-3
Structure and function
Clinical trials on TIM-3 (Table 5)
-
The first study targeting Sym023 was started in 2018 and was intended to investigate the safety and antineoplastic activity of Sym023 on patients suffering from advanced solid tumors or lymphomas (NCT03489343). Twenty-four patients were enrolled and distributed into six groups, each corresponding to a dose level. Two cases (66.7%) in the group with Sym023 1.0 mg/kg and Sym023 3.0 mg/kg each reached SD ≤ 16 weeks. One case in the 0.1 mg/kg group reached SD > 16 weeks. For patients in the 20.0 mg/kg group, there were 83.3% reached SD, but no DLTs were reported. It also reported severe adverse events, including immune-mediated arthritis (1/1), pathological fracture (1/7), back pain (1/6), and spinal cord compression (1/6). In the subsequent trial, researchers could try larger doses of Sym023. The success of Sym023 promoted the studies evaluating the preliminary efficacy of the combined Sym021 (anti-PD-1), Sym022 (anti-LAG-3), and Sym023 in tumor therapies (NCT04641871 and NCT03311412).
-
Novartis also reported the success of anti-TIM-3 antibody MGB453 (Sabatolimab) as a single agent or cooperated with PDR001 in phase I clinical trial in patients suffering advanced malignancies (NCT02608268), in which 219 participants were given MBG453 monotherapy (n = 133) or combination therapy of MBG453 plus PDR001 (n = 86). The result showed that the RP2D for Novartis was selected as 800 mg Q4W. The most common adverse event in the study was treatment-related fatigue (9%, Novartis; 15%, combination). One out of 151 patients in the dose-determining set underwent a DLT: grade 4 myasthenia gravis. Overall, 111 patients (51%) experienced grade 3/4 events. Further studies are warranted to identify how much patients will benefit from MBG453 and PDR001 therapy.
-
Other TIM-3 inhibitors like INCAGN2390, LY3321367, BMS-986258, and SHR1702 are also being tested in phase I trial independently (INCAGN02390, NCT03652077) or in combination with anti-PD-1/PD-L1 mAb (LY3321367, NCT03099109. BMS-986258, NCT03446040. SHR1702, NCT03871855) in advanced malignancies.
CD47
Clinical trials on CD47 (Table 5)
-
The research (NCT02216409) was intended to verify the safety and tolerability of Magrolimab while applied to solid tumors and made a success. Sixty-two patients were treated: 11 in part A, 14 in B, 22 in C, and 15 in the biopsy cohort. In part A, patients were given doses ranging from 0.1 to 3 mg/kg, and finally, 1 mg/kg was decided to be the priming dose. In later parts, patients were tested for a proper maintenance dose, and the result was a priming dose at 1 mg/kg on the first day and followed by maintenance doses of up to 45 mg/kg weekly showed tolerability with patients. Finally, two patients with ovarian/fallopian tube cancers had partial remissions for 5.2 and 9.2 months. Most participants only underwent mild-to-moderate toxicities (grade 1 or 2), including transient anemia (57%), hemagglutination on a peripheral blood smear (36%), fatigue (64%), etc. [164].
-
Advanced studies showed that Magrolimab was applied to patients with non-Hodgkin lymphoma along with Rituximab, Gemcitabine, and Oxaliplatin [165] (NCT02953509). The study enrolled 22 patients, 15 with DLBCL and 7 with follicular lymphoma. All the participants were administered Magrolimab intravenously at a priming dose of 1 mg/kg with weekly maintenance doses of 10 to 30 mg/kg. Researchers reported that the most common toxicity of Magrolimab was the expected on-target anemia and infusion-related reactions, whose intensity was limited to grade 1 or 2. A total of 50% of the patients had an objective response, with 36% having a complete response. The ORR and CR were 40% and 33%, respectively, among patients with DLBCL and 71% and 43%, respectively, among those with follicular lymphoma [165]. More studies are wanted for a more robust outcome. Besides, it is also essential to expand the sample capacity to search for potentially clinically significant safety events.
-
Besides lymphoma, a promising study (NCT04778397) compared the efficacy of Magrolimab + Azacitidine against Venetoclax + Azacitidine in adults with AML, but the outcome remains unknown.
CD93
CD161
B and T lymphocyte attenuator (BTLA)
VTCN1
Clinical trials on B7-H4 (Table 5)
-
An ongoing trial uses anti-B7-H4 antibody FPA150 as a single agent or cooperated with Pembrolizumab in patients with advanced solid tumors (NCT03514121). Twenty-nine patients were enrolled. Researchers did not report any DLTs or grade 4/5 toxicities, ORR was 3%, and DCR was 38% in combination therapy, making FPA150 a good choice for advanced solid cancer tumors.
B7-H3
Clinical trials on B7-H3 (Table 5)
-
In another study (NCT02475213), researchers tried a combination therapy of Enoblituzumab plus Pembrolizumab on patients with advanced solid cancer, including melanoma, NSCLC, HNSCC, and urothelial cancer. One hundred and thirty-three participants joined the phase I study. They all received ≥ 1 dose of study treatment and failed to reach the maximum tolerated dose of Enoblituzumab with Pembrolizumab at 2 mg/kg. In the phase II study, 67 participants (including 21 with HNSCC, 16 with NSCLC, 17 with UC, and 13 with melanoma) were given intravenous Enoblituzumab (15 mg/kg) every three weeks plus Pembrolizumab (2 mg/kg) every three weeks. The result showed that 116 patients (87.2%) suffered treatment-related adverse events, and the percentage was 28.6% for grades ≥ 3. One treatment-related death occurred (pneumonitis). Objective responses occurred in 6 of 18 (33.3% [95% CI 13.3 to 59.0]) patients with checkpoint inhibitor (CPI)-naïve HNSCC and in 5 of 14 (35.7% [95% CI 12.8 to 64.9]) patients with CPI-naïve NSCLC [178]. This phase I/II trial showed that combining Enoblituzumab with Pembrolizumab demonstrated acceptable safety and effect in patients with CPI-naïve HNSCC and NSCLC.